display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - NA - all populationmML - NA - PDL1 positivemML - L2 - all population
pembrolizumab alone KEYNOTE 054 ... KEYNOTE 054 ...
pembrolizumab (10mg/kg) KEYNOTE-006 ... KEYNOTE-002 ...
pembrolizumab (10mg/kg) 2 weeks KEYNOTE-006 ...
pembrolizumab (2mg/kg) KEYNOTE-002 ...

Study type: